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Introduction
STAT3 (Signal transducer and activator of transcrip-
tion 3) is an agent that transmits intercellular signals
and stimulates gene transcription. STAT3 undergoes
activation by phosphorylation of its 705 tyrosine
residue. That recruitment is manifested by transloca-
tion of STAT3 from cytoplasm to nucleus where this
protein acts as nuclear transcription factor. Although it
was reported to be overexpressed in cancer and even
classified as proto-oncogenic protein, [1] the accumu-
lation of STAT3 can be detected in various non neo-
plastic conditions of increased cell turnover and their
enhanced biosynthesis of various proteins [2,3]. That
is why, STAT3 should be viewed as a potent signaling
protein whose presence is common in lots of patholog-
ical and even physiological conditions [4,5]. Neverthe-
less, STAT3 is widely explored in various cancers and
high expression of its active, phosphorylated form was
particularly associated with nodal metastagenicity of
breast cancer [6].
Serine and tyrosine phosphorylation of STAT-3
were triggered by EPO (erythropoietin) [7]. Moreover,
Tyr432 residue on human erythropoietin receptor
(EPOR) was found to activate STAT-3 [8]. EPO is
HIF-1 dependent protein [9]. Hypoxia-inducible factor
1 (HIF-1) is a heterodimer that consists of constitu-
tively expressed subunit beta and hypoxia inducible
subunit alpha. It is an transcriptional factor that causes
transcription of genes that help cell survive the hypox-
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Abstract: STAT3 contributes to increase of EPO expression which is also HIF-1 dependent. EPO receptor activates STAT3.
Expressions of STAT3 and hypoxia induced proteins: HIF-1, EPO and EPOR show mutual correlations in primary ductal
breast cancers, which suggest co-operation among these proteins. Moreover, EPO-EPOR signaling was reported to mediate
cell survival by targeting Bcl-xL in competition with Bax-dependent apoptosis. Our present study was focused on immuno-
histochemical evaluation of STAT3, HIF-1alpha, EPO and EPOR in relation to apoptosis regulators, Bax and Bcl-xL in 39
metastases of ductal breast cancers to lymph nodes. The proteins were abundantly expressed by cancer cells. HIF-1alpha
correlated with EPOR in all and in chemotherapy treated metastases (r=0.428, p=0.007 and r=0.462, p=0.040, respective-
ly). HIF-1 associated significantly with EPO in chemotherapy spared metastases (r=0.549, p=0.015) and comparison
between those proteins almost reached statistical significance in entire number of metastatic breast cancers (r=0.309,
p=0.056). Metastases from T2 primary tumors had significantly higher expressions of HIF-1alpha, EPO and EPOR com-
pared to T1 originating metastases (p=0.020, p=0.028, p=0.021, respectively). Bax correlated with EPO and EPOR in all
studied nodal metastases (r=0.449, p=0.006 and r=0.421, p=0.011, respectively) and so did Bcl-xL with HIF-1alpha
(r=0.440, p=0.007), EPO and EPOR (r=0.383, p=0.021, r=0.495, p=0.002, respectively). Metastatic breast cancers seem to
be areas of intensive signaling by STAT3, HIF-1, EPO and EPOR. Strong Bax and Bcl-xL labeling reflects accelerated cell
turnover in nodal metastases. By means of association with Bcl-xL, HIF-1alpha, EPO and EPOR could favor growth of
nodal metastases and survival of breast cancers cells.
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ia injury [9]. Oxygen deficit is a quite common condi-
tion in rapidly growing tumors with extensive neoplas-
tic spread into lymph nodes and distant organs. HIF-
1α was found to be intensively produced in late stage
node positive breast cancers. Overexpression of HIF-
1alpha was indicator of ominous follow up and signifi-
cant shortening of survival period [10]. Thus, HIF-
1alpha target therapy is expected to be advantageous
for patients with node positive breast cancers [10].
HIF-1 upregulates transcription of angiogenic genes
like erythropoietin (EPO) and vascular endothelial
growth factor (VEGF), which induce sprouting of new
vessels and in result they increase the risk of metastasis
because they boost surface of contact between tumor
cells and vasculature [9]. Moreover, HIF-1, EPO and
EPOR expressions rise together with development of
vascular bed of breast cancers [11-12]. Zhong et al.
reported much higher frequency of HIF-1alpha overex-
pression in breast cancer metastases than primary
breast cancers [13]. That fact also suggested HIF-1 is
more characteristic for invasive phenotype of breast
cancer and more common in metastatic tumors [13]. In
addition, EPO-EPOR signaling was reported to mediate
cell survival by targeting Bcl-xL (B-cell leukemia/lym-
phoma extra long protein) and counteract Bax-depend-
ent (BCL-2-associated X protein) apoptosis [14-15].
Expressions of STAT3, HIF-1alpha, EPO and
EPOR show mutual correlations in primary invasive
ductal breast carcinomas (IDC), which suggests co-
operation among these proteins [16]. Encouraged by
our results in primary tumors, we sued to evaluate
expressions of HIF-1alpha, EPO, EPOR and STAT3 in
their nodal metastases. Our study also incorporates
correlates of mentioned proteins with Bax and Bcl-xL
expression in nodal metastases of ductal breast can-
cers. Rearrangement of expression of apoptosis regu-
lators is quite intensive in metastatic cancer cell popu-
lations which undergo constant and significant renew-
al. Particularly, increased Bax expression is hallmark
of nodal metastagenicity and greater staging and grad-
ing of primary breast cancers [17]. In consequence,
nodal metastases are sensitive to accelerated apoptosis
and subsequent replacement of cell generations due to
rapid speed of metastatic growth and lack of sufficient
framework of vasculature and connective tissue in
lymph nodes. That is why, consistency of nodal metas-
tases is loose and frequently necrotic. In lymph node
metastases of breast cancer Bax and Bcl-xL associated
very closely with Insulin Receptor Substrate 1 that was
reported to correlate positively wit Ki67 labeling as
indicator of breast cancer cell growth in primary
tumors and nodal metastases [18]. Thus, -in our opin-
ion- HIF-1alpha, EPO, EPOR which are hypoxia-
induced rescue proteins for breast cancer cells and
their intracellular mediator STAT3 should be compared
to expression of Bax and Bcl-xL as well. The aim of our
study was to detect and compare STAT3, HIF-1alpha,
EPO, EPOR, Bax and Bcl-xL in 39 local lymph nodes
with metastases of ductal breast cancer with regard to
different characteristics of primary tumors.
Materials and methods
The 39 local, nodal metastases of ductal breast cancers were surgi-
cally removed and evaluated with immunohistochemical staining
for STAT3, HIF-1alpha, EPO, EPOR, Bax and Bcl-xL. Some of
patients were given preoperative chemotherapy. 3-5 μm thick sec-
tions of sampled nodes underwent standard fixation and embed-
ment in paraffin blocks. The slides were dewaxed in xylene and
rehydrated through graded alcohols to phosphate buffered saline
(PBS). Endogenous peroxidase activity was inhibited in specimens
by 2% hydrogen peroxide. Microwaves were applied for 3 minutes
in procedure of EPO antigen retrieval. To eliminate background
effects, the specimens were incubated with blocking serum for 1
hour in case of HIF-1alpha, EPO, EPOR and for 90 minutes in case
of STAT3. STAT3, EPO, EPOR were labeled with specific anti-
HIF-1alpha IgG (sc-10790), anti-STAT3 (sc-7179) IgG anti-EPO,
H-162, anti-EPOR, C-20 (Santa Cruz Biotechnology, Inc.). Dilu-
tion of primary antibodies was 1:500 for STAT3, 1:400 for HIF-
1alpha, 1:150 for EPO, 1:200 for EPOR, 1:100 for Bax and 1:300
for Bcl-xL. Incubation took the whole night at 4°C except for 2
hours long incubation in EPOR evaluation at room temperature.
Bcl-xL and Bax were detected with avidin-biotin-peroxidase com-
plex (ABC Staining System; Santa Cruz Biotechnology, Inc.,
USA) while EnVision (Dako, Denmark) system produced the color
reaction in tissues after 7 minutes of exposure to DAB in case of
HIF-1alpha evaluation, 6 minutes for EPO, 5 minutes for EPOR
and 10 minutes for STAT3 visualization. Sections were counter-
stained with haematoxylin. In negative controls the primary anti-
bodies were not added. Stained specimens of colorectal cancer
were assumed positive controls.
Ethical issues. The studies were performed according to the latest
revision of Declaration of Helsinki from 2004 and permitted by the
local ethical committee at the Medical University of Bialystok.
Scoring and statistical analysis. Relations in pairs of proteins
were analyzed with Spearman's rank correlation test. All the statis-
tical results with p<0.05 were assumed to be significant. 3-grade
scoring system was used as follows: grade 0 if there was less than
10% positive cancer cells; grade 1 if positive cancer cells ranged
from 10 to 50%; grade 2 if 50% malignant cells were positive. The
immunohistochemical reactions were examined by two patholo-
gists in 10 high power fields of each tumor in light microscopy and
the mean rate of tumor positive cells was determined. Chi-square
Pearson's was applied to explore statistically significant differ-
ences of immunoreactivities of each protein apart in regard to clin-
ico-pathological variables. Grading and staging were not able to be
assessed in some of primary tumors in consequence of massive
destruction of the cancer cells by chemotherapy. In result the group
of tumors with determined T and G was smaller and it did not
included tumors of chemotherapy administered patients. All
patients gave informed consent for inclusion in the study. 
Results
HIF-1alpha and STAT3 expressions were of granular
and diffuse pattern of staining in mixed nuclear and
cytoplasmic location in cancer cells, while microgranu-
lar and disperse immunoreactivities of EPO and EPOR
were mostly cytoplasmic with occasional membranous
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enhancement of staining. Bax and Bcl-xL coalesced in
granular fashion in the cytoplasm of breast cancer cells.
The proteins were detected in different rates: HIF-1alpha
in 87% (34/39) EPO in 97% (38/39), EPOR in 95%
(37/38), STAT3 in 64% (25/39), Bax 72% (28/39) and
Bcl-xL 92% (36/39) of all examined nodal metastases.
STAT3 did not correlate with HIF-1alpha and EPOR
in ductal breast cancer metastases to lymph nodes. Any-
way the trend toward positive correlation was marked in
comparison between STAT3 and EPO (r=0.309,
p=0.056). The severely reduced number of nodal metas-
tases did not apparently allow to draw up reliable com-
parisons which were conducted in regard to T and G sta-
tus of corresponding primary breast cancers. The limita-
tion resulted from massive destruction of primary tumors
by chemotherapy. It disables assessment of grading and
staging of primary tumors in regard to expression of
most studied proteins in metastases (Table 1).
HIF-1alpha tended to correlate positively with HIF-
1 depended protein EPO (r=0.309, p=0.056) Further-
more, significant relationship between HIF-1alpha and
EPOR was noted in all studied metastases (r=0.428,
p=0.007)m. The statistical significance was also noted
in comparison of HIF-1alpha and EPO in nodal metas-
tases, which did not underwent chemotherapy
(r=0.549, p=0.015). Reversely, chemotherapy treated
nodal metastases revealed correlation between HIF-
1alpha and EPOR (r=0.462, p=0.040) (Table 2).
Bax correlated with EPO and EPOR in all breast
cancer patients (r=0.449, p=0.006 and r=0.421,
p=0.011, respectively) and so did Bcl-xL with HIF-
1alpha (r=0.440, p=0.007), EPO and EPOR, (r=0.383,
p=0.021, r=0.495, p=0.002, respectively). In opposi-
tion, HIF-1alpha faled to significantly associate with
Bax in all metastatic tumors and STAT3 didn't corre-
late with Bcl-xL and either Bax in all nodal metastases
of colorectal cancers (Table 3 and 4).
Interestingly, metastases, which derived from T2
primary tumors, had significantly higher expression
of hypoxia induced proteins like HIF-1alpha, EPO
and EPOR than T1 originating metastases (p=0.020,
p=0.028, p=0.021, respectively). Immunoreactivity
to STAT3 did not change in nodal metastases due to
varied staging of corresponding primary tumors.
Chemotherapy tended to reduce expression of STAT3
in nodal metastases of breast cancer (p=0.070) with-
out statistical significance, but it did not effect statis-
tics at all in case of HIF-1alpha, EPO and EPOR
(Table 5).
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Table 1. Analysis of correlations between STAT3, HIF-1alpha, EPO and EPOR expressions in nodal metastases of the breast cancer.
Spearman's correlation rank test. 
Table 2. Analysis of correlations between HIF-1α, EPO and EPOR expressions in nodal metastases of the breast cancer. Spearman's cor-
relation rank test.
Discussion
Nodal metastases of ductal breast cancer seem to be
the field of intensive signaling with participation of
STAT3, HIF-1alpha, EPO and EPOR molecules. The
relations between these proteins are highlighted by
positive correlations or trends toward them in our
work. Tight regulation between HIF-1alpha and its
downstream proteins is proved by correlation between
HIF-1alpha and EPOR and the trend toward the signif-
icance between HIF-1alpha and EPO in all nodal
metastases of ductal breast cancer. Considering the
silencing role of chemotherapy, only expression of
STAT3 tended to be reduced in chemotherapy treated
nodal metastases of breast cancer, but this trend was
still below level of statistical significance in our study
(Table 5). Although statistically significant differences
did not occur in comparison of each protein alone in
regard to variable staging in primary breast cancers
[16], expressions of HIF-1alpha, EPO and EPOR were
markedly increased in metastases which originated
from larger T2 primary tumors in our present study. It
seems that cancer cells that came from larger primary
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Table 4. Correlations of Bcl-xL with STAT3, HIF-1alpha, EPO and EPOR expressions in nodal metastases of the breast cancer. Spear-
man's correlation rank test.
Table 3. Correlations of Bax with STAT3, HIF-1alpha, EPO and EPOR expressions in nodal metastases of the breast cancer. Spearman's
correlation rank test.
Table 5. Statistical differences in expression of STAT3, HIF-
1alpha, EPO and EPOR in nodal metastases derived from primary
ductal breast cancers of different variables as histological differen-
tiation G, primary tumor size T, and presence or absence of
chemotherapy. Pearson's Chi-square test.
n – number of cases, G2 – moderately differentiated, G3 – poorly differen-
tiated, T- tumor size, T1 tumor 2cm or less in greatest dimension, T2-
tumor more than 2 cm but not more than 5 cm in greatest dimension. (Ch+)
– chemotherapy treaded cases , (Ch-) – chemotherapy spared cases. 
*The amounts of investigated cancer metastases different and were limited
because G and T were not assessed in certain primary tumors because of
cellular damage due to chemotherapy, that appeared to spare more nodal
metastases than primary foci of cancers.
cancers are better adapted to survive hypoxic injury as
they overexpress cytoprotective proteins like HIF-
1alpha, EPO and EPOR in greater extend than nodal
metastases from smaller T1 tumors.
HIF-1 exerts an impact on cell survival by relations
with apoptosis regulators in colorectal cancers [19]. In
our study, HIF-1alpha was confirmed to promote sur-
vival by positive correlation with Bcl-xL and simulta-
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Fig. 1. Immunohistochemistry showing expression of STAT3 (Fig. 1a), HIF-1alpha (Fig. 1b), EPO (Fig. 1c,), EPOR (Fig 1d), Bax (Fig
1e) and Bcl-xL (Fig 1f) in nodal metastases of ductal breast cancer. (a). Finely granular condensing cytoplasmic staining showing STAT3
expression in metastatic cancer cells. Lymph node metastasis (original magnification × 200). (b). Cytoplasmic, coarse granules and
intense perinuclear rim positive for HIF-1alpha. Metastatic breast cancer cells encircling necrosis in the fashion of comedocarcinoma at
periphery of a lymph node (original magnification × 200Fig. (c). Metastatic breast cancer show peripheral membrane – associated cyto-
plasmic immunostain for EPO in lymph node metastasis of breast cancer (original magnification × 400). (d). Clumped cytoplasmic
immunoreactivity to EPOR in cytoplasm of breast cancer cells. Lymph node metastasis (original magnification × 200). (e). Anti-Bax stain-
ing evenly distributed in manner of fine granules in cytoplasm of breast cancer cells. Lymph node metastasis (original magnification ×
100). (f). Granular focally increased anti-Bcl-xL labeling in cytoplasm of breast cancer cells. Lymph node metastasis (original magnifi-
cation × 200).
neous loss of association with Bax. Lack of EPO,
which signals by its receptor EPOR, was reported to
decrease Bcl-xL but not to affect Bax expression in
HCD-57, a murine erythroid progenitor cell line [20].
Similarly, EPO and EPOR could effect turnover of
breast cancer cells in nodal metastases of our present
study because this ligand and its receptor correlated
with both antiapoptotic Bcl-xL and proapoptotic Bax.
Particularly, linkage of Bax with EPO and EPOR
could point at the possibility that EPO and EPOR
might simultaneously be expressed to counteract cell
death in malignant tumors with high expression of Bax
and their subsequent higher susceptibility to apoptosis.
Lee et al. proved STAT3 involvement in regulation
of Bax and Bcl-xL expression in cell lines of head and
neck squamous cell carcinoma (HNSCC). This report-
ed regulatory function depended on P53 status. Name-
ly, decrease of wild-type P53 was accompanied with
activation of NF-kappaB, STAT3 and Bcl-xL. This
effect was less apparent in HNSCC expressing mutat-
ed type of P53. Reintroduction of wild type P53 down-
regulated STAT3 and Bcl-xL to increase Bax expres-
sion [21]. On the basis of such experiment promotion
of cell survival was attributed to properties of STAT3
[21]. Appliance of STAT3 inhibitors (such as AG490
or WP1066) led to suppression of growth and induc-
tion of apoptosis in malignant gliomas [22]. Abroga-
tion of STAT3 function resulted in increase of Bax
expression and decrease of Bcl-xL [20]. In opposition,
our present investigations were failed to reflect any
impact of STAT3 on Bax and Bcl-xL.
To sum up, STAT3, HIF-1alpha, EPO and EPOR
appear to be associated with one another in studies
over metastases of ductal breast cancer to local lymph
nodes. High rates of Bax and Bcl-xL positive metas-
tases reflect accelerated cell turnover in nodal location
of breast cancers. HIF-1alpha, EPO and EPOR could
favor growth of nodal metastases and survival of
breast cancers cells by means of association with Bcl-
xL and the fact that expressions of HIF-1α, EPO and
EPOR were markedly increased in metastases which
originated from larger T2 primary tumors.
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